NCCN Radiation Therapy Compendium adds nine new clinical practice guidelines in oncology

Apr 19 2017

The National Comprehensive Cancer Network^® (NCCN^®) continues to build its NCCN Radiation Therapy Compendium™ with the publication of radiation therapy (RT) recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®):

• Acute Lymphoblastic Leukemia, Version 2.2016
• Basal Cell Skin Cancer, Version 1.2017
• Dermatofibrosarcoma Protuberans, Version 1.2017
• Gastric Cancer, Version 1.2017
• Hodgkin Lymphoma, Version 1.2017
• Merkel Cell Carcinoma, Version 1.2017
• Ovarian Cancer, Version 1.2017
• Squamous Cell Skin Cancer, Version 1.2017
• Thymomas and Thymic Carcinomas, Version 1.2017

Launched in March 2017, the NCCN Radiation Therapy Compendium™ now includes recommendations from 33 NCCN Guidelines^®. Additional cancer types will be published on a rolling basis over the coming months.

The NCCN Radiation Therapy Compendium™ provides guidance on all RT modalities recommended within the NCCN Guidelines, including Intensity Modulated Radiation Therapy (IMRT), Intra-Operative Radiation Therapy (IORT), Stereotactic Radiosurgery (SRS)/Stereotactic Body Radiotherapy (SBRT)/Stereotactic Ablative Radiotherapy (SABR), Image-guided Radiotherapy (IGRT), Low dose-rate brachytherapy (LDR)/High dose-rate brachytherapy (HDR), Radioisotope, and Particle Therapy.

Transparency of NCCN Guidelines and Compendia development is central to the philosophy, policies, and procedures of NCCN. NCCN posts the policies and processes for developing and maintaining the NCCN Guidelines. These policies are available to the public on the NCCN website. Identification of newly published research, NCCN Member Institution review, external stakeholder submissions, and panel review occur on an ongoing basis with at least annual review performed for NCCN Guidelines for each disease.

The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Other NCCN Guidelines derivative products include:

• NCCN Drugs & Biologics Compendium (NCCN Compendium^®) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer. The NCCN Compendium^® is recognized by public and private insurers alike, including CMS and UnitedHealthcare as an authoritative reference for oncology coverage policy.
• NCCN Biomarkers Compendium^® contains information designed to support decision-making around the use of biomarker testing in patients with cancer.
• NCCN Chemotherapy Order Templates (NCCN Templates^®) include chemotherapy, immunotherapy, supportive care agents, monitoring parameters, and safety instructions based directly on recommendations within the NCCN Guidelines. Special instructions for self-administered chemotherapeutic agents are also provided.
• NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance to support clinical decision-making for patients with cancer. In 2016, NCCN was recognized by Centers for Medicare & Medicaid Services (CMS) as a qualified provider-led entity for creation of imaging AUC.

Source: https://www.nccn.org/